Vicore Pharma announces Last Patient Last Visit in the mechanistic phase II study with C21 in systemic sclerosis
Gothenburg, December 15, 2020 – Vicore Pharma Holding AB (publ), a pharmaceutical company dedicated to developing innovative medicines for serious lung disorders, today announces that the last patient has completed the final visit in the mechanistic phase II study of Raynaud’s phenomenon in systemic sclerosis patients.· The study has been closed with 12 patients having completed the study · Top line data is estimated to be available in February 2021 “After reassuring that the statistical power is sufficient to pick up the signal we are looking for in the study, we decided to stop